迪哲医药: 迪哲医药：信息披露暂缓与豁免业务管理制度

Core Points - The document outlines the information disclosure deferral and exemption management system for Dize (Jiangsu) Pharmaceutical Co., Ltd, aiming to standardize practices and protect the rights of shareholders and creditors [1][2][3] - The company is required to disclose significant events promptly, particularly when a board resolution is made or when relevant parties sign agreements [2][3] - The company can defer disclosure if it poses risks to its interests or could mislead investors, provided that confidentiality agreements are in place [2][3][4] Section Summaries General Provisions - The system is established based on relevant laws and regulations to ensure the company's lawful operation and protect stakeholders' rights [1] - The company can independently determine the need for deferral or exemption without prior application to the Shanghai Stock Exchange, subject to post-event supervision [1][2] Scope of Deferral and Exemption - Significant events must be disclosed at the earliest occurrence of specific milestones, such as board resolutions or when management becomes aware of the event [2] - If confidentiality is compromised or market rumors arise, the company must disclose relevant information within two trading days [2][3] Review Procedures for Deferral and Exemption - The company must carefully assess the need for deferral or exemption and prevent unauthorized disclosure of sensitive information [4][5] - A formal internal registration and approval process is required for any deferral or exemption, ensuring compliance with established criteria [5][6] Accountability and Compliance - The company must maintain a record of deferral and exemption actions and submit relevant materials to regulatory bodies within ten days after reporting periods [6][7] - A mechanism for accountability is established to address non-compliance with disclosure obligations, ensuring that responsible parties face appropriate consequences [6][7]